Vanguard Group’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-872,041
| Closed | -$3.95M | – | 4331 |
|
|
2025
Q3 | $3.95M | Sell |
872,041
-11,896
| -1% | -$35.1K | ﹤0.01% | 3351 |
|
|
2025
Q2 | $1.9M | Sell |
883,937
-145,389
| -14% | -$407K | ﹤0.01% | 3549 |
|
|
2025
Q1 | $4.5M | Sell |
1,029,326
-1,756
| -0.2% | -$7.91K | ﹤0.01% | 3222 |
|
|
2024
Q4 | $4.82M | Buy |
1,031,082
+3,428
| +0.3% | +$23.1K | ﹤0.01% | 3290 |
|
|
2024
Q3 | $7.21M | Buy |
1,027,654
+18,195
| +2% | +$132K | ﹤0.01% | 3113 |
|
|
2024
Q2 | $6.92M | Buy |
1,009,459
+102,308
| +11% | +$951K | ﹤0.01% | 3105 |
|
|
2024
Q1 | $12.8M | Buy |
907,151
+488,248
| +117% | +$7.43M | ﹤0.01% | 2826 |
|
|
2023
Q4 | $3.15M | Hold |
418,903
| – | – | ﹤0.01% | 3446 |
|
|
2023
Q3 | $6.28M | Buy |
418,903
+12,700
| +3% | +$228K | ﹤0.01% | 3154 |
|
|
2023
Q2 | $6.46M | Sell |
406,203
-8,110
| -2% | -$85.3K | ﹤0.01% | 3182 |
|
|
2023
Q1 | $2.97M | Buy |
414,313
+14,010
| +3% | +$99.1K | ﹤0.01% | 3530 |
|
|
2022
Q4 | $2.32M | Buy |
400,303
+182
| +0% | +$1.38K | ﹤0.01% | 3610 |
|
|
2022
Q3 | $3.8M | Sell |
400,121
-15,640
| -4% | -$206K | ﹤0.01% | 3467 |
|
|
2022
Q2 | $4.99M | Buy |
415,761
+62,125
| +18% | +$651K | ﹤0.01% | 3373 |
|
|
2022
Q1 | $4.63M | Sell |
353,636
-70,859
| -17% | -$1.04M | ﹤0.01% | 3572 |
|
|
2021
Q4 | $7.47M | Sell |
424,495
-13,381
| -3% | -$268K | ﹤0.01% | 3393 |
|
|
2021
Q3 | $9.5M | Buy |
437,876
+3,299
| +0.8% | +$84.2K | ﹤0.01% | 3275 |
|
|
2021
Q2 | $15.2M | Sell |
434,577
-23,827
| -5% | -$1.28M | ﹤0.01% | 2986 |
|
|
2021
Q1 | $45.2M | Buy |
458,404
+10,509
| +2% | +$1.26M | ﹤0.01% | 2376 |
|
|
2020
Q4 | $48.6M | Buy |
447,895
+9,779
| +2% | +$1.21M | ﹤0.01% | 2217 |
|
|
2020
Q3 | $45.1M | Buy |
438,116
+53,473
| +14% | +$8.01M | ﹤0.01% | 2070 |
|
|
2020
Q2 | $80.3M | Buy |
384,643
+66,817
| +21% | +$11.8M | ﹤0.01% | 1775 |
|
|
2020
Q1 | $31.1M | Buy |
317,826
+46,139
| +17% | +$5.38M | ﹤0.01% | 2077 |
|
|
2019
Q4 | $31.3M | Sell |
271,687
-2,535
| -0.9% | -$223K | ﹤0.01% | 2321 |
|
|
2019
Q3 | $14.9M | Buy |
274,222
+21,774
| +9% | +$2.45M | ﹤0.01% | 2612 |
|
|
2019
Q2 | $30M | Buy |
252,448
+40,697
| +19% | +$3.37M | ﹤0.01% | 2338 |
|
|
2019
Q1 | $11.1M | Buy |
211,751
+47,044
| +29% | +$1.9M | ﹤0.01% | 2766 |
|
|
2018
Q4 | $5.19M | Sell |
164,707
-59,895
| -27% | -$2.44M | ﹤0.01% | 3075 |
|
|
2018
Q3 | $13.6M | Buy |
224,602
+4,269
| +2% | +$240K | ﹤0.01% | 2769 |
|
|
2018
Q2 | $11.7M | Buy |
220,333
+38,595
| +21% | +$2.32M | ﹤0.01% | 2824 |
|
|
2018
Q1 | $10.5M | Buy |
181,738
+96,027
| +112% | +$5.98M | ﹤0.01% | 2806 |
|
|
2017
Q4 | $3M | Sell |
85,711
-4,675
| -5% | -$154K | ﹤0.01% | 3305 |
|
|
2017
Q3 | $3.3M | Buy |
90,386
+35,611
| +65% | +$988K | ﹤0.01% | 3261 |
|
|
2017
Q2 | $1.37M | Sell |
54,775
-8,255
| -13% | -$226K | ﹤0.01% | 3501 |
|
|
2017
Q1 | $1.7M | Buy |
63,030
+14,452
| +30% | +$411K | ﹤0.01% | 3425 |
|
|
2016
Q4 | $1.41M | Sell |
48,578
-17,241
| -26% | -$563K | ﹤0.01% | 3475 |
|
|
2016
Q3 | $2.71M | Sell |
65,819
-3,160
| -5% | -$120K | ﹤0.01% | 3281 |
|
|
2016
Q2 | $2.18M | Buy |
68,979
+1,424
| +2% | +$64.3K | ﹤0.01% | 3355 |
|
|
2016
Q1 | $3.49M | Buy |
67,555
+7,721
| +13% | +$431K | ﹤0.01% | 3140 |
|
|
2015
Q4 | $5.7M | Buy |
59,834
+3,555
| +6% | +$312K | ﹤0.01% | 2929 |
|
|
2015
Q3 | $4.64M | Buy |
56,279
+3,512
| +7% | +$449K | ﹤0.01% | 3003 |
|
|
2015
Q2 | $8.57M | Buy |
52,767
+5,993
| +13% | +$2.02M | ﹤0.01% | 2761 |
|
|
2015
Q1 | $19M | Buy |
46,774
+30,773
| +192% | +$13M | ﹤0.01% | 2350 |
|
|
2014
Q4 | $8.64M | Buy |
16,001
+823
| +5% | +$317K | ﹤0.01% | 2606 |
|
|
2014
Q3 | $5.19M | Buy |
+15,178
| New | +$4.52M | ﹤0.01% | 2799 |
|
Vanguard Group's ADVM Position: Q4 2025 in Review
Vanguard Group sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 872,041 shares — an estimated $3.95M sold.
Vanguard Group first reported a position in ADVM in Q3 2014 and held it in 45 quarters. The position peaked at $80.3M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Vanguard Group reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Vanguard Group sold 872,041 Adverum Biotechnologies shares in Q4 2025, an estimated $3.95M.
- Vanguard Group first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 45 quarters.
- Vanguard Group's Adverum Biotechnologies position peaked at $80.3M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.